



## **ASX Announcement**

25 January 2021

### **Notification of Quarterly Reports and Investor Conference Call**

***Hexima will release its Quarterly Cash Flow and Activity reports and hold an investor conference call on 29 January 2021.***

MELBOURNE, AUSTRALIA (25 January 2021): Hexima Limited (ASX:HXL) a clinical stage biotechnology company developing HXP124, a new prescription treatment for onychomycosis, today advises that it will release its Appendix 4C Quarterly Cash Flow Report and Quarterly Activity Report for the period ending 31 December 2020 on Friday 29 January 2021.

Investors are invited to join a conference call on Friday 29 January 2021 at 9:00 AM AEDT with Hexima's CEO, Michael Aldridge, and Hexima's COO, Nicole van der Weerden.

Please register for the call using the following link:

<https://s1.c-conf.com/diamondpass/10012033-6482fg.html>

After registering you will receive a confirmation email containing information about joining the call.

#### **About Hexima**

Hexima is a biotechnology company engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial of HXP124 for onychomycosis. Hexima holds granted, long-life patents protecting HXP124 in major markets globally. For additional information about Hexima please visit [www.hexima.com.au](http://www.hexima.com.au).

**This announcement is authorised for release to ASX by Michael Aldridge, Managing Director & Chief Executive Officer.**

#### ***Enquiries:***

Dr Nicole van der Weerden

Chief Operating Officer

[n.vanderweerden@hexima.com.au](mailto:n.vanderweerden@hexima.com.au)

***Join our email database to receive company announcements:***

[Info@hexima.com.au](mailto:Info@hexima.com.au)

[www.hexima.com.au](http://www.hexima.com.au)